Our CSO/CTO, Juan Carlos Ramirez, gave an oral presentation under the theme line “ Beyond 2020: Disruptive technologies”.

During this event, different experts and cutting-edge Companies analyzed the newest technologies that will change our way of producing, working and consuming in the next years.

Juan Carlos Ramirez, VIVEbiotech´s CSO/CTO, has just published a new paper entitled “Gene Editing and CRISPR Therapeutics: Strategies Taught by Cell and Gene Therapy”.

This chapter offers a brief overview of some of the factors that have contributed to a rapid entry into the biotech and pharmaceutical company’s pipeline, focusing on how cell and gene therapies (CGT), collectively known as advanced therapies, have become the driving forces toward the therapeutic uses of gene editing technology.

VIVEbiotech´s exhibited at BioEurope 2017 event, the most relevant event in the Biotechnology field in Europe that took place in Berlin from the 5th to the 8th of November.

More than two thousand biotech Companies were present at BioEurope, among them, very well-known Companies involved in the Gene Therapy field.

VIVEbiotech´s team exhibited at  European Society Gene and Cell Therapy (ESGCT) event that was hold in Berlin from the 16th to the 20th of October 2017.

Juan Carlos Ramirez (CSO/CTO) and Natalia Elizalde (Business Development Director) attended this congress.

Two collaborative profiles have been published today in Enterprise European Network (EEN).

The Enterprise European Network  helps businesses innovate and grow on an international scale. It is the world’s largest support network for small and medium-sized enterprises (SMEs) with international ambitions. 

Different Biotechnology Companies have actively participated in extended report from the Diario Vasco daily newspaper. Among these Companies, VIVEbiotech´s CEO, put a reasoned viewpoint  considering that there are some Companies, as VIVEbiotech, that have been seeding during years allowing that Guipuzcoa is already a relevant area in the biotechnology sector.